Trials / Completed
CompletedNCT00440011
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 266 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bimatoprost 0.03% eye drops | bimatoprost 0.03% 1 drop nightly for 3 months |
| DRUG | travoprost 0.004% eye drops | travoprost 0.004% 1 drop nightly for 3 months |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2007-02-26
- Last updated
- 2019-04-25
- Results posted
- 2008-09-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00440011. Inclusion in this directory is not an endorsement.